Cibinqo (Abrocitinib)

Adults with refractory, moderate-to-severe atopic dermatitis, for whom the use of biologics or other systemic pharmacological products is not recommended, or for whom the illness is not sufficiently managed with conventional therapies, may be treated with CIBINQO, a Janus kinase (JAK) inhibitor. 

Use Restrictions: It is not advised to combine CIBINQO with other immunosuppressants, biologic immunomodulators, or JAK inhibitors. 

Recommended Dosage: Dosage:

• The standard dosage for CIBINQO is 100 mg, to be taken orally once daily. In cases where patients do not demonstrate an adequate response to the standard 100 mg dose, a higher dosage of 200 mg orally once daily is recommended.
• For individuals with moderate renal impairment, the suggested initial dosage is 50 mg once daily. However, if the response is insufficient, the dosage may be increased to 100 mg once daily.
• For CYP2C19 poor metabolizers, the recommended starting dosage is 50 mg once daily. Depending on individual response, the dosage may be adjusted to 100 mg once daily.

Administration:

CIBINQO is administered orally. It is important to adhere to the prescribed dosage and administration schedule as directed by the healthcare provider. Prior to initiating CIBINQO, it is essential to conduct the recommended testing, evaluations, and procedures outlined in the Full Prescribing Information. Additionally, for any necessary modifications to the dosage due to specific adverse reactions, healthcare professionals should refer to the detailed information provided in the Full Prescribing Information.

• Serious Infections: CIBINQO may cause severe infections. Avoid in active infections. Monitor closely for signs, and discontinue if serious infection occurs.
• Tuberculosis: Assess for TB before starting. Not recommended for active TB. Treat latent TB before initiating CIBINQO.
• Viral Reactivation: Watch for herpes virus reactivation. Screen for hepatitis B. Discontinue if reactivation occurs.
• Mortality: In older patients, CIBINQO may be associated with higher mortality. Consider risks and benefits.
• Malignancy: Increased risk of non-melanoma skin cancer and lymphomas. Regular skin exams are advised.
• Cardiovascular Events: Higher rates of major adverse cardiovascular events reported. Evaluate risks, especially in smokers.
• Thrombosis: Risk of deep venous thrombosis and pulmonary embolism. Avoid in patients at risk of thrombosis.
• Laboratory Abnormalities: Monitor blood abnormalities and lipid levels. Discontinue for certain abnormalities.
• Immunizations: Complete vaccinations before starting CIBINQO. Avoid live vaccines during therapy.

If you are considering the import of Cibinqo (Abrocitinib) to India, please be aware that Cibinqo can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

Required Documentation for Import:

• A valid prescription from a qualified medical practitioner.
  
• Diagnostic reports of the patient.
  
• Government-issued identification proof for the patient, as recognized by the Government of India.

The order for Cibinqo (Abrocitinib)  will be confirmed upon the receipt of the following documents:

• A valid prescription from a qualified doctor.
  
• An import permit, if applicable.

Cibinqo (Abrocitinib) is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Cibinqo (Abrocitinib)can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Cibinqo (Abrocitinib)

(prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.

Indian Pharma Network is proficient in sourcing Cibinqo (Abrocitinib) from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient’s address, exclusively from New Delhi, India.

Is Cibinqo FDA approved?

Based on data from three controlled clinical trials with a total of 1615 patients enrolled that supported efficacy and safety, the FDA authorized CIBINQO. 

What is Cibinqo’s success rate?

A total of 24% of patients on placebo, 46% of patients on 200 mg, and 39% of patients on 100 mg all had an Investigator Global Assessment response rate of 0 or 1. In terms of Eczema Area and Severity Index scores, 64% of those taking 100 mg, 71% of those taking 200 mg, and 41% of those taking a placebo had a 75% improvement.

Is Cibinqo safe?

Patients receiving CIBINQO treatment may be more susceptible to serious infections that could result in hospitalization or even death; pneumonia, herpes simplex, and herpes zoster were the most common serious infections associated with CIBINQO.

What is CIBINQO and what is it used for?

CIBINQO is a medication used for the treatment of atopic dermatitis. It helps manage symptoms in patients with this skin condition.

How should I take CIBINQO?

CIBINQO is taken orally, with the recommended dosage being 100 mg once daily. Your healthcare provider may adjust the dosage based on your response to treatment. It’s essential to follow their instructions carefully.

Are there any potential side effects of CIBINQO?

Like any medication, CIBINQO may have side effects. Serious infections, viral reactivation, and laboratory abnormalities are possible. It’s crucial to be aware of potential risks and promptly report any unusual symptoms to your healthcare provider.

Can I use CIBINQO if I have a history of infections or other health conditions?

Before starting CIBINQO, inform your healthcare provider about your medical history, especially if you have a history of serious infections, tuberculosis exposure, or chronic conditions. Your healthcare provider will assess the risks and benefits to determine if CIBINQO is suitable for you. Regular monitoring will be important during treatment.